Catherine Gerald Mkindi (PhD student)
Supported by the European and Developing Countries' Clinical Trials Partnership (EDCTP) Strategic Primer Grant number: SP_2011_41304_047
Based at: Ifakara Health Institute, Bagamoyo Tanzania and University of Basel (Switzerland)
Supervisor: Dr Claudia Daubenberger, University of Basel
Description of malaria peptide P27A specific immune responses delivered with Alhydrogel or GLA-SE in Tanzanian volunteers.
The main objective of the study is:
To evaluate immunogenicity of a novel Plasmodium falciparum synthetic peptide vaccine candidate P27A administered with GLA-SE or Alhydrogel adjuvants against blood stage parasites in malaria exposed Tanzanian adults.
The specific objectives are:
- To evaluate induction of P27A specific antibodies and determin their immunoglobulin subclasses.
- To determine if produced antibodies inhibit parasite growth in vitro.
- To measure P27A specific T cell proliferation in peripheral blood mononuclear cells.
- To measure intracellular cytokine production in vaccine induced P27A specific T cells in peripheral blood mononuclear cells.
Catherine Gerald Mkindi was born in Arusha, Tanzania in 1978. After becoming a Bachelor of Veterinary Medicine at Sokoine University, she completed a Diploma Programme for Agricultural and Natural Resources Transformation for Improved Livelihood at University of Life Sciences in Norway in 2008. Returning to Sokoine University she obtained a master degree in veterinary medicine in 2009, and is now a PhD candidate at the University of Basel, Swiss Tropical and Public Health Institute.